NO20071120L - En renset arabinogalaktan-protein (AGP) sammensetning. - Google Patents

En renset arabinogalaktan-protein (AGP) sammensetning.

Info

Publication number
NO20071120L
NO20071120L NO20071120A NO20071120A NO20071120L NO 20071120 L NO20071120 L NO 20071120L NO 20071120 A NO20071120 A NO 20071120A NO 20071120 A NO20071120 A NO 20071120A NO 20071120 L NO20071120 L NO 20071120L
Authority
NO
Norway
Prior art keywords
agp
inhibition
arabinogalactan protein
purified arabinogalactan
composition
Prior art date
Application number
NO20071120A
Other languages
English (en)
Inventor
Sudershan Kumar Arora
Vandita Srivastava
Sameer Shankar Walunj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of NO20071120L publication Critical patent/NO20071120L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

Det beskrives et renset arabinogalaktanprotein-(AGP-) preparat som er isolert ved en selektiv metode fra bladene og/eller stengler av Argemone mexicana-planten. Det beskrives videre et renset arabinogalaktanprotein-(AGP) preparat som er isolert fra bladene og/eller stenglene av Argemone mexicana-planten og som har en eller flere av de følgende effekter: immunsuppresjon, lymfoprolifereringsinhibering, cytokinmodulering som IL-2-inhibering, IFN??- inhibering eller IL-10-induksjon; keratinocyttprolifereringsinhibering, keratolytisk aktivitet og inhibitorisk aktivitet i museøre-svelletesten (MEST).
NO20071120A 2004-09-01 2007-02-27 En renset arabinogalaktan-protein (AGP) sammensetning. NO20071120L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/931,814 US7601368B2 (en) 2004-09-01 2004-09-01 Purified Arabinogalactan-Protein (AGP) composition useful in the treatment psoriasis and other disorders
PCT/IN2005/000132 WO2006025068A1 (en) 2004-09-01 2005-04-26 A purified arabinogalactan-protein (agp) composition

Publications (1)

Publication Number Publication Date
NO20071120L true NO20071120L (no) 2007-05-14

Family

ID=35943518

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071120A NO20071120L (no) 2004-09-01 2007-02-27 En renset arabinogalaktan-protein (AGP) sammensetning.

Country Status (19)

Country Link
US (4) US7601368B2 (no)
EP (1) EP1789439B1 (no)
JP (1) JP2008511613A (no)
KR (1) KR20070059062A (no)
CN (1) CN101044161A (no)
AP (1) AP2007003929A0 (no)
AT (1) ATE452142T1 (no)
AU (1) AU2005278780A1 (no)
BR (1) BRPI0514347A (no)
CA (1) CA2577134A1 (no)
DE (1) DE602005018375D1 (no)
EA (1) EA012208B1 (no)
IL (1) IL181230A0 (no)
MX (1) MX2007002428A (no)
NO (1) NO20071120L (no)
TN (1) TNSN07079A1 (no)
UA (1) UA86986C2 (no)
WO (1) WO2006025068A1 (no)
ZA (1) ZA200701311B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2399993T3 (es) 2007-03-02 2013-04-04 Protectimmun Gmbh Composición farmacéutica para la protección frente a alergias y enfermedades inflamatorias
FR2938192B1 (fr) 2008-11-07 2012-08-24 Expanscience Lab Nouvel actif anti-vergetures et compositions le comprenant
WO2010020379A1 (en) * 2008-08-16 2010-02-25 Protectimmun Gmbh Composition for prevention and treatment of allergic and/or inflammatory diseases
US8609159B2 (en) 2010-05-05 2013-12-17 Comvita New Zealand Limited Immunostimulatory compositions and methods of use thereof
FR2975004B1 (fr) * 2011-05-13 2013-06-28 Expanscience Lab Nouvel actif anti-rougeurs et compositions cosmetiques le comprenant
ITMI20112216A1 (it) 2011-12-05 2013-06-06 Fond Salvatore Maugeri Clinic A Del Lavoro E Composizione comprendente un estratto di chelidonium majus e copaiba e il suo impiego per il trattamento di disfunzioni cutanee
WO2014190398A1 (en) * 2013-05-31 2014-12-04 The University Of Melbourne Inhibition of amyloid fibril formation
EP3176175B1 (en) 2015-12-01 2020-07-01 Ruhr-Universität Bochum Method for synthetically producing arabinogalactan compounds derived from plants and uses of said compounds for the prophylaxis of allergic reactions
WO2017093276A1 (en) 2015-12-01 2017-06-08 Protectimmun Gmbh Method for synthetically producing arabinogalactan compounds derived from plants and uses of said compounds for the prophylaxis of allergic reactions
JP6230638B2 (ja) * 2016-02-12 2017-11-15 株式会社らいむ 神経伸長促進剤、内服剤、培地用添加剤、細胞希釈液用添加剤、培地および細胞希釈液
CN108603115A (zh) 2016-02-12 2018-09-28 来姆有限公司 神经生长促进剂及其制造方法、内服剂、培养基用添加剂、细胞稀释液用添加剂、培养基、细胞稀释液、抗氧化剂及其制造方法、外用剂、以及伤口治疗剂及其制造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818533A (en) * 1985-07-09 1989-04-04 Vipont Pharmaceutical, Inc. Production of high purity alkaloids
US5494671A (en) * 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
JP3177642B2 (ja) * 1991-09-10 2001-06-18 ライオン株式会社 抗男性ホルモン剤
WO2001000682A1 (en) 1999-06-30 2001-01-04 Pharmagenesis, Inc. Hematopoietic arabinogalactan composition
JP4477354B2 (ja) 2002-01-10 2010-06-09 ルピン・リミテッド 乾癬を含む様々な疾患を処置するための薬草組成物、その調製方法およびそのような疾患を処置するための方法

Also Published As

Publication number Publication date
DE602005018375D1 (de) 2010-01-28
MX2007002428A (es) 2007-05-11
TNSN07079A1 (en) 2008-06-02
IL181230A0 (en) 2007-07-04
JP2008511613A (ja) 2008-04-17
CA2577134A1 (en) 2006-03-09
EP1789439B1 (en) 2009-12-16
BRPI0514347A (pt) 2008-06-10
KR20070059062A (ko) 2007-06-11
AU2005278780A1 (en) 2006-03-09
US20090270330A1 (en) 2009-10-29
EP1789439A1 (en) 2007-05-30
UA86986C2 (ru) 2009-06-10
EA012208B1 (ru) 2009-08-28
US7601368B2 (en) 2009-10-13
US20090264341A1 (en) 2009-10-22
ZA200701311B (en) 2009-08-26
US20060045930A1 (en) 2006-03-02
WO2006025068A1 (en) 2006-03-09
WO2006025068A8 (en) 2006-04-20
US20100330650A1 (en) 2010-12-30
EA200700532A1 (ru) 2007-08-31
CN101044161A (zh) 2007-09-26
AP2007003929A0 (en) 2007-02-28
ATE452142T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
NO20071120L (no) En renset arabinogalaktan-protein (AGP) sammensetning.
NO20013003L (no) Kinolin-derivater
WO2003084922A8 (de) Acyl-4-carboxy-phenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
WO2003027247A3 (en) Modulation of stem cells using zinc finger proteins
DK1768500T3 (da) Sammensætninger egnet til behandling af kutane tegn på aldring
DK0813525T3 (da) Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
TW200621253A (en) 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2005069835A3 (en) Bioactive compositions from theacea plants and processes for their production and use
WO2000059899A8 (fr) Nouveaux derives de l'acide lipoïque et les compositions pharmaceutiques les contenant
WO2005012242A3 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
MY151984A (en) Non-anticoagulant polysaccharide compositions
WO2006031926A3 (en) Methods for the isolation and expansion of cord blood derived t regulatory cells
WO2007144779A3 (en) Compositions comprising porphyra and methods of making and using thereof
AU2003234956A1 (en) Pesticidal pyridinecarboxamide derivatives
NO20060821L (no) Heparinavledede oligosakkaridblandinger, fremstilling derav og farmasoytiske preparater inneholdende nevnte blandinger
WO2005018535A3 (en) Compositions and methods for treatment of severe acute respiratory syndrome (sars)
BRPI0516933A (pt) métodos para o isolamento da haptoglobina humana, dos isoformas de hp humana individuais, e da albumina e da haptoglobina humana a partir da fração v de cohn humana, e, produto
DK1082337T3 (da) 17-beta-amino- og hydroxylamino-11-beta-arylsteroider og deres derivater, som har agonistiske eller antagonistiske, hormonale egenskaber
WO2005020685A3 (en) Composition and method for crop protection
WO2002001951A3 (en) Optically pure(-) clethodim, compositions and methods for controlling plant growth comprising the same
GB2441600A (en) A purified arabinogalactan-protein (AGP) composition.
WO2007106675A3 (en) Composition and method of retarding viral activity and reducing viral replication
NO20062639L (no) Bicykliske pyraxoloncytokininhibitorer
AU2020268896A8 (en) Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application